Originally established as a private investment vehicle associated with a European entrepreneurial family, over the past two decades, Orchis has participated in the creation, financing and growth of numerous biotechnology, pharmaceutical and medical technology companies.

Today, Orchis combines venture building, technology development, intellectual property management and commercial strategy within a single integrated structure. The company develops and manages a portfolio of projects and business units addressing critical challenges in human and animal health, with a particular focus on antimicrobial resistance, infectious diseases, metabolic health and longevity.

A distinguishing characteristic of Orchis is its ability to combine scientific excellence with entrepreneurial execution. The company manages an international network of academic researchers, industry experts and strategic partners across Europe, Africa, Asia and Latin America. This network enables efficient project execution, access to world-class scientific capabilities and regional commercialization opportunities.

Beyond Life Sciences, Orchis may selectively invest in emerging technologies and growth opportunities where strong value creation potential exists.

Orchis pursues a long-term value creation strategy based on disciplined capital allocation, active operational involvement and the translation of scientific innovation into commercially successful products and businesses. To support this strategy, Orchis has established dedicated business platforms including Orchis Health & Sports Marketing (OHSM), the group’s commercialization platform for health, wellness and performance-oriented products.

The ultimate objective is not only to generate sustainable financial returns but also to develop technologies and therapies that make a measurable difference to human and animal health worldwide.